Drug
Rezivertinib clinical trials
Also written BPI-7711.
- studies test it
- 5
- open now
- 1
- in phase 3
- 2
- first study started
- 2017
Keep track of what changes. Save the rezivertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 1
Beta Pharma Shanghai (3) · Beta Pharma, Inc. (1) · The First Affiliated Hospital of Guangzhou Medical University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rezivertinib is read from its arms, and is right about nine times in ten.
Testing it · 5
- Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsNot yet recruitingPhase 3The First Affiliated Hospital of Guangzhou Medical UniversityNCT06955325Written as Rezivertinib
- A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer PatientsStatus unknownPhase 3Beta Pharma ShanghaiNCT03866499Written as BPI-7711
- A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation PositiveCompletedPhase 2Beta Pharma ShanghaiNCT03812809Written as BPI-7711
- BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung CancerCompletedPhase 1/2Beta Pharma ShanghaiNCT03386955Written as BPI-7711 Capsule
- A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711CompletedPhase 1Beta Pharma, Inc.NCT04135820Written as BPI-7711
Given in every arm · 1 — rezivertinib is usual care beside what is tested
Codes
What other systems call rezivertinib · ClinicalTrials.gg INT002033
- UNII (FDA) U65F5M6BD5REZIVERTINIBOne source FDA
- NCI Thesaurus C154286RezivertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U65F5M6BD5 | REZIVERTINIB | One source FDA |
| NCI Thesaurus | C154286 | Rezivertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.